（1）免疫检查点PD-1/PD-L1小分子抑制剂的发现、优化和活性评估
（2）新型免疫检查点靶标的成药性研究

免疫检查点疗法是一种新型的免疫疗法，通过调节人体自身免疫系统，清除肿瘤细胞，具有毒副作用低，适应症广泛等优点。
孙博士与其课题组，基于PD-1/PD-L1蛋白结构和相互作用模式，利用骨架跃迁、生物电子等排等经典策略，设计合成了一系列结构新颖的PD-L1小分子抑制剂，完成了蛋白、细胞和动物水平的系统评估，同时，成功获得并解析了优选化合物与PD-L1的共晶结构，阐明了其抗癌作用机制。此研究为开发新型抗癌药物提供了良好的候选药物。

1.Sun C.#, Cheng Y.#, Liu X.#, Wang G., Min W., Wang X., Yuan K., Hou Y., Li J., Zhang H., Dong H., Wang L., Lou C., Sun Y., Yu X., Deng H.*, Xiao Y.*, Yang P.*. Novel phthalimides regulating PD-1/PD-L1 interaction as potential immunotherapy agents. Acta Pharm Sin B 2022, https://doi.org/10.1016/j.apsb.2022.04.007 (IF = 14.9033)
2.Hou Y.#, Zhang F.#, Min W.#, Yuan K., Kuang W., Wang X., Zhu Y., Sun C., Xia F., Wang Y., Zhang H., Wang L., Yang P.*. Discovery of Novel Phosphoinositide-3-Kinase α Inhibitors with High Selectivity, Excellent Bioavailability, and Long-Acting Efficacy for Gastric Cancer. J. Med. Chem. 2022, https://doi.org/10.1021/acs.jmedchem.2c00549 (IF = 8.0385)
3.Li J.#, Wang X.#, Ding J., Zhu Y., Min W., Kuang W., Yuan K., Sun C., Yang P.*, Development and clinical advancement of small molecules for ex vivo expansion of hematopoietic stem cell. Acta Pharmaceutica Sinica B 2022, 12(6): 2808-2831 (IF = 14.9033)
4.Yuan K.#, Li Z.#, Kuang W.#, Wang X.#, Ji M., Chen W., Li J., Min W., Sun C., Ye X., Lu M., Wang L., Ge H., Jiang Y.*, Hao H.*, Xiao Y.*, Yang P.*. Targeting dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) with a highly selective inhibitor for the treatment of prostate cancer, Nat. Commun. 2022, 13:2903 (IF = 17.6939)
5.Hou Y., Kuang W., Min W., Liu Z., Zhang F., Yuan K., Wang X., Sun C., Cheng H., Wang L., Xiao Y., Pu S.*, Xin G.*, Yang P.*, Design, Synthesis, and Biological Evaluation of Icaritin Derivatives as Novel Putative DEPTOR Inhibitors for Multiple Myeloma Treatment, J. Med. Chem. 2021, 64, 14942−14954 (IF = 8.0385)